Ovarian Cancer

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

Floortje J. Backes, MD, discusses other potential roles for mirvetuximab soravtansine and other antibody-drug conjugates in ovarian cancer.

Floortje J. Backes, MD, discusses data for mirvetuximab soravtansine in FRα-positive, platinum-sensitive ovarian cancer

Floortje J. Backes, MD, discusses how to approach FRα testing in ovarian cancer.

Floortje J Backes, MD, discusses how mirvetuximab soravtansine has affected the management of platinum-resistant ovarian cancer.

Floortje J Backes, MD, discusses current treatment considerations for platinum-resistant ovarian cancer.

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer.

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.

Azenosertib (ZN-c3) monotherapy was active in heavily pretreated patients with cyclin E1–positive platinum-resistant ovarian cancer.

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Judy Hayek, MD, explains the rationale of a retrospective analysis evaluating laparoscopic vs open surgery in advanced ovarian cancer.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.